Engellau L, Albrechtsson U, Höjgård S, Norgren L, Larsson E-M
Department of Radiology, Lund University Hospital, Lund, Sweden.
Int Angiol. 2003 Mar;22(1):36-42.
Endovascular repair of abdominal aortic aneurysms (AAA) necessitates a long-term follow-up. These patients are often old and renal insufficiency is not unusual. Cost-effectiveness needs to be addressed in evaluating methods of follow-up. The aim of this study was to compare costs of 5 years follow-up with magnetic resonance imaging with contrast enhanced three-dimensional magnetic resonance angiography (MRI/MRA) with follow-up using CT with DSA, or CTA. We also assessed the impact of contrast media induced (CMI) nephropathy on follow-up costs.
We have implemented Swedish costs of CT with DSA, and CTA on the reported follow-up examinations from the EUROSTAR progress report 2000. The costs of follow-up with CT with DSA, or CTA were compared to a follow-up protocol with MRI/MRA. A cost analysis including a risk analysis of CMI nephropathy was made between MRI/MRA and CT with DSA, or CTA.
Excluding the risk of CMI nephropathy, the 5 years follow-up cost in Euro ( ) with MRI/MRA ( 5715) is substantially higher than CT with DSA ( 3 095) or CTA ( 3573). The cost analysis favours MRI/MRA if the risk of CMI nephropathy from CT with DSA, or CTA is more than 5%.
MRI/MRA can be cost-effective for follow-up of endovascularly repaired AAA depending on the risk of CMI nephropathy for CT with DSA, and CTA. MRI/MRA should be the method of choice for patients with pre-existing renal insufficiency.
腹主动脉瘤(AAA)的血管内修复需要长期随访。这些患者往往年龄较大,肾功能不全并不罕见。在评估随访方法时需要考虑成本效益。本研究的目的是比较采用磁共振成像联合对比增强三维磁共振血管造影(MRI/MRA)进行5年随访的成本与采用CT联合DSA(CTA)进行随访的成本。我们还评估了对比剂诱导的肾病(CMI)对随访成本的影响。
我们根据2000年欧洲血管内支架治疗腹主动脉瘤注册研究(EUROSTAR)进展报告中所报道的随访检查,采用瑞典CT联合DSA以及CTA的成本数据。将CT联合DSA或CTA的随访成本与采用MRI/MRA的随访方案进行比较。对MRI/MRA与CT联合DSA或CTA之间进行了成本分析,包括CMI肾病的风险分析。
不考虑CMI肾病的风险,采用MRI/MRA进行5年随访的成本(5715欧元)显著高于采用CT联合DSA(3095欧元)或CTA(3573欧元)。如果CT联合DSA或CTA导致CMI肾病的风险超过5%,成本分析则支持采用MRI/MRA。
根据CT联合DSA和CTA导致CMI肾病的风险,MRI/MRA对于血管内修复的AAA患者随访可能具有成本效益。对于已存在肾功能不全的患者,MRI/MRA应作为首选方法。